It sensitizes anti-programmed death-ligand 1 (PD-L1) therapy by inhibiting exosomal secretion of PD-L1 by cancers [170], and also reduces glioma progression by promoting the cellular retention of tumor-suppressing miRNA [171]. Here, CD274 is linked to central nervous system cancer.